Biocon Limited launches Liraglutide GLP-1 in the Netherlands for diabetes and obesityBiocon Limited launches Liraglutide GLP-1 in the Netherlands for diabetes and obesity

Introduction

leading biopharmaceutical firm announced the launch of GLP 1 drug Liraglutide in Netherlands for diabetes and obesity following approval from the Medicines Evaluation Board

Also Read: Lloyds Engineering Works gains 4% after incorporating new defence unit

Share price movement of Biocon

On December 15, 2025, Biocon Limited opened at ₹387.45, up 0.21% from its previous close of ₹386.65. The stock hit a high of ₹388.60, up 0.50%, and a low of ₹384.60. By 10:35 AM, it traded at ₹384.60, down 0.53%, with a market capitalisation of ₹51,419.62 crore.

Biocon launches Liraglutide in Netherlands

Biocon Limited announced the launch of its GLP-1 peptide Liraglutide in the Netherlands. The product targets diabetes and obesity and is introduced through its distribution partner Pharmamedic B.V.

The drug-device combination will be marketed as Diavorin for diabetes and Vobexoryn for chronic weight management. The launch follows approval from the Medicines Evaluation Board, Netherlands, received earlier this year.

This marks the first European Union country where Biocon will directly launch Liraglutide under its own brand. The product is indicated for diabetes management and chronic weight control.

Liraglutide is a synthetic GLP-1 analog administered once daily by injection. It received European Union approval in 2009 and United States approval in 2010 for medical use.

Stock performance of Biocon for Period of 1 week, 6 months, and 1 year

Biocon Ltd delivered a 0.66% return over the past week, gained 13.0% over the past six months, and rose 9.51% over the past year.

Also Read: Diamond Power Infrastructure gains after new cable order from Amara Raja Infra

Shareholding pattern of Biocon

Particulars	Sep 2025	Jun 2025	Mar 2025
Promoter	54.50%	54.50%	54.50%
FII	6.60%	6.00%	7.00%
DII	22.10%	22.80%	21.50%
Public	16.70%	16.50%	16.90%
Others	0%	0.20%	0.20%

About Biocon

Biocon Limited (NSE: BIOCON) is a global biopharmaceutical company focused on biologics, biosimilars and complex therapies for chronic diseases, with operations across India, the United States and Europe.

Stay Ahead with the Latest Stock Market Updates – Click Here

Disclaimer: The above article is written for educational purposes, and the companies’ data mentioned in the article may change with respect to time. The securities quoted are exemplary and are not recommendatory.

FAQs